Barry J. Byrne

26.2k citations

310 papers · 17.8k indexed · 8 hit papers · h-index 67

Genetics top 0.2%
- Virus-based gene therapy research 96
- Neurogenetic and Muscular Disorders Research 36
Genetics top 0.05%
- Virus-based gene therapy research 96
- Neurogenetic and Muscular Disorders Research 36
Molecular Biology top 0.2%
- Muscle Physiology and Disorders 35
- Viral Infectious Diseases and Gene Expression in Insects 32
- Mitochondrial Function and Pathology 28
Physiology top 0.5%
- Lysosomal Storage Disorders Research 94
Cardiology and Cardiovascular Medicine top 1%
- Viral Infections and Immunology Research 24
Rheumatology
- Glycogen Storage Diseases and Myoclonus 56

Co-authors: Paul Kessler Kevin S. Cahill Catalin Toma Mark F. Pittenger Nicholas Muzyczka Terence R. Flotte Irene Zolotukhin Sergei Zolotukhin
Cited by: Genetics Molecular Biology
Journals: Proceedings of the National Academy of Sciences (8 papers)Journal of Biological Chemistry (5 papers)Circulation (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Barry J. Byrne

293 papers receiving 17.4k citations

Hit Papers

8 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2023 Molecular Therapy
2020 Molecular Therapy
2008 Proceedings of the National Academy of Sciences
2008 Human Gene Therapy
2002 Nature Medicine
2002 Circulation
1999 Gene Therapy
1996 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Barry J. Byrne

Since Specialization

Citations

This map shows the geographic impact of Barry J. Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry J. Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry J. Byrne more than expected).

Fields of papers citing papers by Barry J. Byrne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry J. Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry J. Byrne. The network helps show where Barry J. Byrne may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Barry J. Byrne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barry J. Byrne Line = papers co-authored together Barry J. Byrne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cardiac Transplantation Does Not Improve Exercise Tolerance, Muscle Mass, or Substrate Metabolism in Barth Syndrome JIMD Reports ·W. Todd Cade,Kathryn L. Bohnert,Linda R. Peterson,Lisa de las Fuentes,Emily Poehlein,Cynthia L. Green,Christina A. Pacak,Barry J. Byrne,Dominic N. Reeds,Adil Bashir,Brian Feingold,Carolyn L. Taylor	2025	0
2	Overexpression of Wild-Type TMEM43 Improves Cardiac Function in Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Circulation Research ·Laura Lalaguna,Miquel Arenas,Marina López‐Olañeta,María Villalba‐Orero,R. J. Jiménez Riobóo,María Victoria Gómez‐Gaviro,Joan Isern,Pura Muñoz‐Cánoves,Barry J. Byrne,Juan Pablo Ochoa,Pablo García‐Pavía,Enrique Lara‐Pezzi	2025	2
3	Neurological glycogen storage diseases and emerging therapeutics Neurotherapeutics ·Matthieu Colpaert,Pankaj K. Singh,Katherine J. Donohue,Natacha T Pires,David D. Fuller,Manuela Corti,Barry J. Byrne,Ramon C. Sun,Craig W. Vander Kooi,Matthew S. Gentry	2024	5
4	Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease Journal of Patient-Reported Outcomes ·Priya S. Kishnani,Barry J. Byrne,Kristl G. Claeys,Jordi Díaz‐Manera,Mazen M. Dimachkie,Hani Kushlaf,Tahseen Mozaffar,Mark Roberts,Benedikt Schoser,Noemi Hummel,Agnieszka Kopiec,Fred Holdbrook,Simon Shohet,António Toscano,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2024	3
5	Codon-Optimized and de novo–Synthesized E-Selectin/AAV2 Dose–Response Study for Vascular Regeneration Gene Therapy Annals of Surgery ·Francesca A. Voza,Barry J. Byrne,Yulexi Y. Ortiz,Yan Li,Nga Le,Lucy Osafo,Antoine C. Ribieras,Hongwei Shao,Carlos Theodore Huerta,Yuntao Wei,Gustavo Falero-Díaz,Andres Franco-Bravo,Roberta M. Lassance‐Soares,Roberto I. Vázquez-Padrón,Zhaojun Liu,Omaida C. Velázquez	2024	3
6	Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy International Journal of Molecular Sciences ·Laurent Servais,Lindsey Lair,Anne M. Connolly,Barry J. Byrne,Karen Chen,Vlad Coric,Irfan Qureshi,Susan Durham,Daniel Campbell,Grant Maclaine,Jackie Marin,Clifford Bechtold	2024	8
7	Innate Immune Sensing of Adeno-Associated Virus Vectors Human Gene Therapy ·Di Cao,Barry J. Byrne,Ype P. de Jong,Cox Terhorst,Dongsheng Duan,Roland W. Herzog,Sandeep Kumar	2024	18
8	Meeting Report: 2022 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Transfer Therapy’ Journal of Neuromuscular Diseases ·Angela Lek,Evrim Atas,Sharon Hesterlee,Barry J. Byrne,Carsten G. Bönnemann	2023	23
9	Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02) Journal of Neurology ·Barry J. Byrne,Benedikt Schoser,Priya S. Kishnani,Drago Bratkovic,Paula R. Clemens,Özlem Göker-Alpan,Xue Ming,Mark S. Roberts,Matthias Vorgerd,Kumaraswamy Sivakumar,Ans T. van der Ploeg,Mitchell Goldman,Jacquelyn Wright,Fred Holdbrook,Vipul Jain,Elfrida R. Benjamin,Franklin K. Johnson,Sheela Sitaraman Das,Yasmine Wasfi,Tahseen Mozaffar	2023	14
10	Elevated liver glycogenolysis mediates higher blood glucose during acute exercise in Barth syndrome PLoS ONE ·George G. Schweitzer,Grace L. Ditzenberger,Curtis C. Hughey,Brian N. Finck,Michael R. Martino,Christina A. Pacak,Barry J. Byrne,W. Todd Cade	2023	2
11	Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies Journal of Clinical Investigation ·Stephanie M. Salabarria,Manuela Corti,Kirsten E. Coleman,Megan B. Wichman,Julie Berthy,Precilla D’Souza,Cynthia J. Tifft,Roland W. Herzog,Melissa E. Elder,Lawrence R. Shoemaker,Carmen Leon‐Astudillo,Fatemeh Tavakkoli,David H. Kirn,Jonathan D. Schwartz,Barry J. Byrne	2023	67
12	Adeno-Associated Virus (AAV) Capsid Stability and Liposome Remodeling During Endo/Lysosomal pH Trafficking Viruses ·Bridget Lins-Austin,Saajan Patel,Mario Mietzsch,Dewey Brooke,Antonette Bennett,Balasubramanian Venkatakrishnan,Kim Van Vliet,Adam N. Smith,Joanna Long,Robert McKenna,Mark Potter,Barry J. Byrne,Sanford L. Boye,Brian Bothner,Regine Heilbronn,Mavis Agbandje‐McKenna	2020	44
13	Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy Current Gene Therapy ·Angela L. McCall,Sylvia Stankov,Gabrielle Cowen,Denise Cloutier,Zizhao Zhang,Lin Yang,Nathalie Clément,Darin J. Falk,Barry J. Byrne	2019	18
14	Atomic structure of a rationally engineered gene delivery vector, AAV2.5 Journal of Structural Biology ·M.J. Burg,Claire Rosebrough,Lauren M. Drouin,Antonette Bennett,Mario Mietzsch,Paul R. Chipman,Robert McKenna,Duncan Sousa,Mark Potter,Barry J. Byrne,R. Jude Samulski,Mavis Agbandje‐McKenna	2018	24
15	Systemic Delivery of AAVB1- GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease Human Gene Therapy ·Allison M. Keeler,Marina Zieger,Sophia H. Todeasa,Angela L. McCall,Jennifer C. Gifford,Samantha Birsak,Sourav Choudhury,Barry J. Byrne,Miguel Sena‐Esteves,Mai K. ElMallah	2018	41
16	Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- hGAA ) Gene Therapy in Children Affected by Pompe Disease PubMed ·Manuela Corti,Cristina Liberati,Barbara K. Smith,Lee Ann Lawson,İbrahim Sacit Tuna,Thomas J. Conlon,Kirsten E. Coleman,Saleem Islam,Roland W. Herzog,David D. Fuller,Shelley Collins,Barry J. Byrne	2017	90
17	Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning PubMed ·Manuela Corti,Brian Cleaver,Nathalie Clément,Thomas J. Conlon,Kaitlyn J. Faris,Gensheng Wang,Janet M. Benson,Alice F. Tarantal,Davis Fuller,Roland W. Herzog,Barry J. Byrne	2015	79
18	Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV- GAA ) Gene Vector in Patients with Pompe Disease PubMed ·Barry J. Byrne,Barbara K. Smith,Cathryn Mah,Lee Ann Lawson,Saleem Islam,Manuela Corti,Daniel Martı́n,Nicole Dobija,Maria V. Irwin,Thomas J. Conlon,Brian Cleaver,Nathalie Clément,Shelley Collins	2014	34
19	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis Blood ·Rachel T. McGrath,Maartje van den Biggelaar,Barry J. Byrne,Jamie M. O’Sullivan,Orla Rawley,Richard O’Kennedy,Jan Voorberg,Roger J. S. Preston,James S. O’Donnell	2013	52
20	Preclinical Toxicology and Biodistribution Studies of Recombinant Adeno-Associated Virus 1 Human Acid α-Glucosidase PubMed ·Thomas J. Conlon,Kirsten Erger,Stacy Porvasnik,Travis Cossette,Cheryl Roberts,Lynn A. Combee,Saleem Islam,Jeffry S. Kelley,Denise Cloutier,Nathalie Clément,Corinne R. Abernathy,Barry J. Byrne	2013	16

About Barry J. Byrne

Barry J. Byrne is a scholar working on Genetics, Genetics and Physiology, having authored 310 papers that have together received 17.8k indexed citations. Recurring topics across this work include Virus-based gene therapy research (96 papers), Lysosomal Storage Disorders Research (94 papers), Glycogen Storage Diseases and Myoclonus (56 papers), Neurogenetic and Muscular Disorders Research (36 papers), Muscle Physiology and Disorders (35 papers), Viral Infectious Diseases and Gene Expression in Insects (32 papers), Mitochondrial Function and Pathology (28 papers) and Viral Infections and Immunology Research (24 papers). The work is most often cited by research in Genetics (2.6k citations), Genetics (6.7k citations) and Molecular Biology (10.8k citations). Barry J. Byrne has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Paul Kessler, Kevin S. Cahill, Catalin Toma, Mark F. Pittenger, Nicholas Muzyczka, Terence R. Flotte, Irene Zolotukhin, Sergei Zolotukhin, Thomas J. Conlon and Cathryn Mah. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact